Stay updated with breaking news from Kaplan Meier. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New and Recurrent Patients Treated with UGN-102 Achieved Similar Durability of Response Rates at 12 months ...
Treatment with 177Lu-PNT2002 resulted in a significant improvement in radiographic progression-free survival vs abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer whose disease had progressed on an androgen receptor pathway inhibitor.
The FDA has issued a complete response letter to the biologic license application seeking the approval of cosibelimab for use in patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not eligible for curative surgery or radiation.
WILMINGTON, Del. & WALTHAM, Mass.--(BUSINESS WIRE)--Dec 10, 2023--
- Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first six months of treatment - Data are...